DNTHHIGH SIGNALOPERATIONAL10-K

DNTH has rebranded its lead drug candidate from DNTH103 to claseprubart and introduced a second clinical-stage candidate DNTH212, while experiencing significant financial deterioration with net losses nearly doubling and R&D expenses increasing 75%.

The company appears to be in an advanced stage of clinical development with two distinct therapeutic candidates targeting different mechanisms in autoimmune diseases, suggesting pipeline maturation and diversification. However, the substantial increase in losses and R&D spending, combined with declining revenue, indicates the company is in a cash-intensive phase of drug development that will likely require additional financing.

Comparing 2026-03-09 vs 2025-03-11View on EDGAR →
FINANCIAL ANALYSIS

DNTH's financial position shows mixed signals with cash increasing significantly to $51.1M (likely from financing activities), but operating performance deteriorated substantially with net losses expanding from $85M to $162M and R&D expenses surging 75% to $146M. Revenue declined 67% to just $2M while operating cash burn increased to $129M, indicating the company is deep in the clinical development phase and burning through capital rapidly. The substantial cash increase suggests recent fundraising, but the elevated burn rate will require careful monitoring of runway duration.

FINANCIAL STATEMENT CHANGES
Cash & Equivalents
Balance Sheet
+124.1%
$22.8M$51.1M

Cash position surged 124.1% — strong cash generation or capital raise providing significant financial cushion.

Accounts Receivable
Balance Sheet
-93.6%
$807K$52K

Receivables declined — improved collection efficiency or conservative revenue recognition.

Net Income
P&L
-91.1%
-$85.0M-$162.3M

Net income declined 91.1% — review whether driven by operations, interest costs, or non-recurring items.

R&D Expense
P&L
+75.2%
$83.1M$145.6M

R&D investment increased 75.2% — signals commitment to future product development, though near-term margin impact.

Capital Expenditure
Cash Flow
-75.2%
$1.3M$314K

Capex reduced 75.2% — investment cycle winding down or capital discipline; may improve near-term free cash flow.

Operating Income
P&L
-74.7%
-$101.9M-$177.9M

Operating income deteriorated sharply — investigate whether driven by one-time charges or structural cost issues.

Total Liabilities
Balance Sheet
+74.3%
$21.5M$37.5M

Liabilities grew 74.3% — significant increase in debt or obligations, assess impact on financial flexibility.

Revenue
P&L
-67.3%
$6.2M$2.0M

Revenue declined 67.3% — significant demand weakness or market share loss warrants investigation.

Current Liabilities
Balance Sheet
+66.6%
$18.5M$30.7M

Current liabilities surged 66.6% — significant near-term obligations; verify ability to meet short-term debt.

Operating Cash Flow
Cash Flow
-65.1%
-$78.2M-$129.1M

Operating cash flow fell 65.1% — earnings quality concerns; investigate working capital changes and non-cash items.

LANGUAGE CHANGES
NEW — 2026-03-09
PRIOR — 2025-03-11
ADDED
Overview We are a clinical-stage biotechnology company dedicated to developing potentially best-in-class therapies for patients living with severe autoimmune diseases.
Our lead clinical-stage candidate, claseprubart, is a monoclonal antibody that is purposefully engineered with extended half-life, improved potency, and high selectivity for only the active C1s complement protein ( C1s ) enabling less frequent and more convenient self-administered subcutaneous ( S.C.
Additionally, selective inhibition of the classical complement pathway may lower patient risk of infection from encapsulated bacteria by preserving immune activity of the lectin and alternative pathways.
We believe claseprubart has the potential to address a broad array of complement-dependent diseases as currently available therapies and those in development leave room for improvements in efficacy, safety, and/or dosing convenience.
Our second clinical-stage candidate, DNTH212, is a first and potentially best-in-class, bifunctional fusion protein that targets plasmacytoid dendritic cell ( pDC ) BDCA2 to reduce Type 1 interferon production, while simultaneously inhibiting BAFF/APRIL to suppress B cell function.
+7 more — sign up free →
REMOVED
trade policies including tariffs and other trade restrictions or the threat of such actions, instability in financial institutions, the prospect of a shutdown of the U.S.
Overview We are a clinical-stage biotechnology company focused on developing next-generation complement therapeutics for patients living with severe autoimmune and inflammatory diseases.
We believe our lead novel and proprietary monoclonal antibody product candidate, DNTH103, has the potential to address a broad array of complement-dependent diseases as currently available therapies and those in development leave room for improvements in efficacy, safety, and/or dosing convenience.
We have purposefully engineered DNTH103 to selectively bind to only the active form of the C1s complement protein ( C1s ) and to exhibit improved potency and an extended half-life.
By selectively targeting only the active form of C1s, which drives disease pathology and constitutes only a small fraction of the total protein present in circulation, we aim to reduce the amount of drug required for a therapeutic effect.
+7 more — sign up free →
MORE OPERATIONAL SIGNALS
HOFTHIGHHOFT completed a major divestiture of its Pulaski and Samuel Lawrence furniture ...
2026-04-17
CTRNHIGHCTRN underwent a dramatic operational turnaround with a complete repositioning f...
2026-04-15
ORBSHIGHORBS has undergone a complete business transformation from packaging and e-comme...
2026-04-15
BRFHHIGHBRFH completed a transformative acquisition of Arps Dairy in October 2025, drama...
2026-04-15
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →